DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study on Vonoprazan in the Real-world Clinical Practice in China

Completed

Conditions: Esophagitis Peptic

First Posted Date: 2020-08-06

Last Posted Date: 2023-10-25

Lead Sponsor: Takeda

Target Recruit Count: 3000

Registration Number: NCT04501627

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
🇨🇳
Heilongjiang Provincial Hospital (Nanshang), Harbin, Heilongjiang, China
🇨🇳
Wenzhou Central Hospital, Wenzhou, Zhejiang, China

and more 37 locations

A Study of TAK-951 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: TAK-951
Drug: TAK-951 Placebo

First Posted Date: 2020-07-27

Last Posted Date: 2023-03-10

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT04486950

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Conditions: Myelodysplastic Syndromes

First Posted Date: 2020-07-23

Last Posted Date: 2022-09-30

Lead Sponsor: Takeda

Registration Number: NCT04484363

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Phase 1

Withdrawn

Conditions: Coronavirus Disease

Interventions: Drug: TAK-671
Drug: TAK-671 Placebo

First Posted Date: 2020-07-09

Last Posted Date: 2020-10-08

Lead Sponsor: Takeda

Registration Number: NCT04464460

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: TAK-935

First Posted Date: 2020-07-08

Last Posted Date: 2022-01-11

Lead Sponsor: Takeda

Target Recruit Count: 33

Registration Number: NCT04461483

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan

Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants

Completed

Conditions: Healthy Volunteers
Narcolepsy Type 1

Interventions: Device: Portable EEG Device
Device: Portable ECG Device
Device: Accelerometry

First Posted Date: 2020-06-24

Last Posted Date: 2021-05-07

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT04445129

Locations: 🇺🇸
Research Carolina Elite, LLC, Denver, North Carolina, United States
🇺🇸
Delta Waves Sleep Disorders and Research Center, Colorado Springs, Colorado, United States
🇺🇸
Intrepid Research, Cincinnati, Ohio, United States

and more 10 locations

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-788

First Posted Date: 2020-06-22

Last Posted Date: 2021-09-05

Lead Sponsor: Takeda

Target Recruit Count: 14

Registration Number: NCT04441255

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Neoplasms

Interventions: Drug: Dazostinag
Drug: Pembrolizumab
Drug: Platinum
Drug: 5-fluorouracil

First Posted Date: 2020-06-09

Last Posted Date: 2025-02-28

Lead Sponsor: Takeda

Target Recruit Count: 374

Registration Number: NCT04420884

Locations: 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 64 locations

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Biological: TAK-102

First Posted Date: 2020-05-28

Last Posted Date: 2024-07-31

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT04405778

Locations: 🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

Withdrawn

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: TAK-573
Drug: Bortezomib
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2020-05-19

Last Posted Date: 2020-07-14

Lead Sponsor: Takeda

Registration Number: NCT04392648

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy